[Modern Fixed Combinations in the Correction of Arterial Hypertension and Dyslipidemia]

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Arterial hypertension and dyslipidemia are significant risk factors for cardiovascular diseases.
• Ischemic heart disease often coexists with arterial hypertension, necessitating targeted therapeutic strategies.

Purpose of the Study:

• To present a clinical case demonstrating the individual selection of effective therapy for a patient with arterial hypertension and dyslipidemia.
• To evaluate the appropriateness of a fixed triple combination therapy in managing combined cardiovascular risk factors.

Main Methods:

• A clinical case report approach was utilized.
• Therapeutic selection was based on patient-specific risk factors and clinical guidelines.
• Equamer® (amlodipine + lisinopril + rosuvastatin) was chosen as the fixed-combination therapy.

Main Results:

• The selected fixed triple combination therapy (amlodipine, lisinopril, rosuvastatin) was deemed highly appropriate for the patient's clinical profile.
• This combination effectively targets both arterial hypertension and dyslipidemia, major contributors to cardiovascular risk.

Conclusions:

• Individualized therapy selection is crucial for managing complex cardiovascular conditions.
• Fixed triple combination therapy, such as Equamer®, offers a rational approach to addressing multiple cardiovascular risk factors simultaneously.